The Homozygous Familial Hypercholesterolemia (HoFH) drugs in development market research report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Homozygous Familial Hypercholesterolemia (HoFH). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued products.
GlobalData tracks 23 drugs in development for Homozygous Familial Hypercholesterolemia (HoFH) by 23 companies/universities/institutes. The top development phase for Homozygous Familial Hypercholesterolemia (HoFH) is phase iii with eight drugs in that stage. The Homozygous Familial Hypercholesterolemia (HoFH) pipeline has 22 drugs in development by companies and one by universities/ institutes. Some of the companies in the Homozygous Familial Hypercholesterolemia (HoFH) pipeline products market are: Amgen, Akeso and Sanofi.
The key targets in the Homozygous Familial Hypercholesterolemia (HoFH) pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3), and Low Density Lipoprotein Receptor (LDLR).
The key mechanisms of action in the Homozygous Familial Hypercholesterolemia (HoFH) pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with eight drugs in Pre-Registration. The Homozygous Familial Hypercholesterolemia (HoFH) pipeline products include three routes of administration with the top ROA being Subcutaneous and eight key molecule types in the Homozygous Familial Hypercholesterolemia (HoFH) pipeline products market including Monoclonal Antibody, and Small Molecule.
Homozygous Familial Hypercholesterolemia (HoFH) overview
Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder caused by receiving a mutation of the FH gene from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain, and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.
For a complete picture of Homozygous Familial Hypercholesterolemia (HoFH)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
